We identified cabozantinib as a potent inhibitor of wild-type ROS1 kinase and the L2026M and G2032R mutants that confer acquired clinical resistance to crizotinib by screening a library of existing targeted therapies. A patient with ROS1-rearranged NSCLC who progressed on crizotinib was treated with cabozantinib and experienced a partial response. Cabozantinib is a more potent inhibitor of G2032R and L2026M mutant, crizotinib-resistant ROS1 compared to brigatinib, entrectinib, and PF-06463922, and should be evaluated in ROS1 rearranged crizotinib resistant patients. The identification of new uses for existing targeted therapies in such patients is a way to rapidly deliver new treatments to the clinic, while avoiding the high cost of de novo drug development. This strategy may also be deployed to overcome resistance to targeted therapies across a variety of oncogene-addicted cancers. 
Identification of existing drugs that effectively target NTRK1-and ROS1-rearrangements in lung cancer

STATEMENT OF TRANSLATIONAL RELEVANCE
We identified cabozantinib as a potent inhibitor of wild-type ROS1 kinase and the L2026M and G2032R mutants that confer acquired clinical resistance to crizotinib by screening a library of existing targeted therapies. A patient with ROS1-rearranged NSCLC who progressed on crizotinib was treated with cabozantinib and experienced a partial response. Cabozantinib is a more potent inhibitor of G2032R and L2026M mutant, crizotinib-resistant ROS1 compared to brigatinib, entrectinib, and PF-06463922, and should be evaluated in ROS1 rearranged crizotinib resistant patients. The identification of new uses for existing targeted therapies in such patients is a way to rapidly deliver new treatments to the clinic, while avoiding the high cost of de novo drug development. This strategy may also be deployed to overcome resistance to targeted therapies across a variety of oncogene-addicted cancers. 
INTRODUCTION
Oncogenic driver mutations are found in approximately 50% of patients with non-small cell lung cancer (NSCLC) (1) . Patients with activating mutations in EGFR or ALKrearrangements respond to targeted therapies like erlotinib and crizotinib, respectively, but the development of resistance ultimately limits the clinical efficacy of these drugs (2) . Beyond the more common NSCLC driver mutations in EGFR and KRAS, and ALK-rearrangements, a significant, but albeit smaller, group of patients are found to have alterations in ROS1, NTRK1,
HER2, BRAF, RET, and MET (1).
The identification and regulatory approval of new therapies directed against less common oncogenic drivers, and any resistance mechanisms that may emerge, is complicated by the high cost and protracted time required to develop a new drug. Development of a new cancer drug, including highly targeted agents, may take up to 7 years and cost tens of millions of dollars (3).
This presents a challenge to the treatment of patients with rare oncogenic drivers in lung cancer, who will eventually succumb to disease progression due to different mechanisms of acquired resistance.
One way to address this problem is to identify new uses for existing drugs. Because the clinical and pharmacologic properties of existing drugs are defined, any new use may rapidly be brought to the clinic. Examples of off-target inhibition by kinase inhibitors include crizotinib, which was initially developed to target MET, and later found to block ALK and ROS1 (4, 5) , and imatinib, initially developed against ABL, and later found to inhibit PDGFR and KIT (6) . ROS1-rearrangements are reported in glioblastoma, cholangiocarcinoma, gastric adenocarcinoma, ovarian serous tumors, inflammatory myofibroblastic tumors, and chronic myelomonocytic leukemia (7) .
After preclinical studies demonstrated crizotinib inhibits ROS1 kinase (5, 8) , a phase II study of NSCLC patients with ROS1-rearrangements treated with crizotinib was initiated. This study demonstrated an impressive 72% response rate to crizotinib treatment with a 19.2 month progression-free survival (9) . Despite the success of crizotinib in ROS1-rearranged NSCLC, patients inevitably develop acquired resistance either through the L2026M "gatekeeper" mutation, alteration of another active site residue (G2032R), or undefined changes (10) .
A number of methods have been used to design more potent inhibitors or to overcome crizotinib resistance in ROS1-rearranged NSCLC, including de novo drug discovery (11) and screens of existing kinase inhibitors (12, 13) . The c-MET and VEGFR-2 inhibitor foretinib potently inhibits wild-type and G2032R-mutant ROS1 (12) . Foretinib reached phase II clinical trials in breast and lung cancer. However, because of its lack of clinical activity in unselected populations, its clinical development was discontinued. There are two ROS1 specific inhibitors undergoing clinical development: the dual ALK1/ROS1 inhibitor PF-06463922 (NCT01970865) and entrectinib (RXDX-101/NMS E628), a pan-TRK, ALK, and ROS1 inhibitor (STARTRK-1, NCT02097810).
NTRK1 (TRKA, neurotrophic tyrosine kinase receptor 1) fusions with different partners, including CD74 and MPRIP, were identified in lung cancer in 2013. NTRK1 rearrangements are thought to occur in 1-3% of patients with NSCLC (14) . Under normal circumstances, the TRK family of kinases play a role in the development of the central and peripheral nervous systems and in pain sensation (15) . NTRK1 fusions have also been identified in thyroid, colon and ovarian cancer, melanoma, cholangiocarcinoma, glioblastoma, and acute myeloid leukemia (15) .
The activity of the fusion kinase is inhibited by crizotinib and lestaurtinib, and TRK-specific inhibitors such as entrectinib, AZD7451, and ARRY-470 are among at least 9 compounds undergoing clinical development.
In an effort to further accelerate development of drugs that target ROS1 and NTRK1 in lung cancer, including resistant variants of ROS1, a library of existing targeted therapies was 
MATERIALS AND METHODS
Proliferation assays
Ba/F3 cells (immortalized murine bone-marrow derived pro-B cells) transfected with either CD74-ROS1 or CD74-NTRK1 were used for screening and were prepared as previously described (14) . An expanded version of the KIN001 library, which is composed of commercially-available and in-house kinase inhibitors, was used for screening (18) . Highthroughput screening was performed in duplicate in 384-well plates with 1,000 cells/well and a final DMSO concentration < 0.5%. Cells and drug were incubated for 72 hours, and viability was measured using CellTiter Glo. IC 50 experiments were performed in triplicate, were calculated using a sigmoidal, non-linear dose-response model in GraphPad Prism, and are presented as the mean of 3 separate experiments. The CUTO-3 cell line was the generous gift of Dr. Robert C. Doebele. The UMG-118 and HCC-78 cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, Virginia) and passaged in our laboratory for less than 6 months; ATCC uses short tandem repeat profiling for cell line authentication.
Western blot analysis
Cells were incubated with inhibitor for 6 hours. Cell lysate (prepared by 30 minute incubation with 0.1% Triton X-100 + protease inhibitor) was loaded into each well of a 4-12% Bis-Tris gel.
Gels were transferred to PVDF membranes, blocked with 5% milk, and incubated with a 1:1,000 dilution of primary antibody and a 1:5,000 secondary antibody solution.
Structural modeling
Molecular docking studies of cabozantinib on the wild-type ROS1 and point-mutated (L2026M and G2032R) kinase domain were performed. In order to construct a homology model, structures of the wild-type ROS1 and point-mutated (L2026M and G2032R) ROS1 kinase domain, the 3D structure of the template kinase c-Met in the DFG out conformations (PDB accession code: 3LQ8) was retrieved from the Protein Data Bank. Sequence alignments of ROS1 and the template protein were generated using the Discovery Studio 4.1 package. 3D model structures of wild-type and point-mutated (L2026M and G2032R) ROS1 kinase domain were built-up using the Modeler in Discovery Studio 4.1 package, and were further refined by using the CHARMM force field. The 3D structure of cabozantinib was built using Maestro build panel and energy-minimized using the Impact module of Maestro in the Schrödinger suite program. Ligand docking onto the active site of wild-type and point-mutated (L2026M and G2032R) ROS1 kinase domain was carried out using the Schrödinger docking program, Glide.
The best-docked poses were selected as the lowest Glide score.
Genetic profiling
OncoPANEL is a hybrid capture targeted next generation sequencing assay to detect somatic mutations, copy number variations and structural variants in tumor DNA extracted from fresh, frozen, or formalin-fixed paraffin-embedded samples (19) . DNA was isolated from tissue containing at least 20% tumor nuclei and analyzed by massively parallel sequencing using a solution-phase Agilent SureSelect hybrid capture kit and an Illumina HiSeq 2500 sequencer.
The studies were performed in a CLIA certified laboratory, and the resulting sequences were interpreted by a board-certified anatomic pathologist. The patient provided consent to clinical and research use of the genomic findings, which were approved by the Dana-Farber Harvard Cancer Center Institutional Review Board.
Creation of NTRK1 gatekeeper mutation
The pDNR-dual plasmid containing wild-type CD74-NTRK1 kinase was used for site directed mutagenesis of Phe589 to Val. The mutated CD74-NTRK1 fusion was then transferred to the JP1540 vector using Cre recombination (New England Biolabs) and transformed into E coli.
Plasmid was purified and then transfected using the FuGene reagent (Promega, Madison, Wisconsin) into 293 cells. Protein expression and kinase activity was assessed as described above. 
RESULTS
Identification of targeted agents that inhibit ROS1 and NRTK1 kinase activity
putative gatekeeper residue in the NTRK1 kinase active site based on the available crystal structure ( Figure 2E ). This residue was mutated to valine, and the effect of inhibitors identified in our screen were assessed on NTRK1 autophosphorylation in 293 cells transiently transfected with both wild-type and F589V CD74-NTRK1. As seen in Figure 2F , the F589V mutation did not affect inhibition of NTRK1 autophosphorylation by lestaurtinib or BMS-536924.
Lead compounds inhibit ROS1 signaling
The most potent agents identified were cabozantinib, foretinib, and brigatinib (AP26113) for ROS1, with little inhibition seen of the parental Ba/F3 cells by these compounds (Figure 3 , Table 1 , Supplementary Figure 4 ). Cabozantinib and foretinib exhibited potent activity against both wild-type ROS1 and the two reported kinase mutants that confer acquired resistance to crizotinib, the G2032R and L2026M mutations, as previously reported (20) . In contrast, PF- 
cells. PF-06463922 inhibited wild-type and L2026M mutant ROS1 autophosphorylation and ERK activation, with little effect on signaling in the G2032R mutant, and entrectinib was only effective at blocking activity of wild-type ROS1 signaling (Supplementary Figure 5) .
Inhibition of ROS1 signaling in human cancer cells bearing ROS1-rearrangements
The effect of cabozantinib, crizotinib, and foretinib were next studied in the NSCLC HCC78 cell line, which expresses the SLC34A2-ROS1 fusion, and in the UMG-118 glioblastoma cell line, which expresses the FIG-ROS1 fusion. As seen in the CD74-ROS1 transformed Ba/F3 cells, brigatinib, cabozantinib, crizotinib, and foretinib showed similar inhibition of HCC78 proliferation ( Figure 3C ), ROS1 autophosphorylation, and downstream ERK activation ( Figure   3D ). The IC 50 for inhibition of HCC78 observed for these drugs is similar to that reported by others (12) , and is up to ~150-fold less potent than in CD74-ROS1-transformed Ba/F3 cells, likely due to activation of other signaling pathways. Inhibition of ROS1 autophosphorylation and ERK activation is also seen in the UMG-118 cell line (Supplementary Figure 6) .
Modeling of cabozantinib in the ROS1 active site reveals the molecular basis for inhibition of wild-type and mutant kinase
To define the molecular basis for the inhibition, cabozantinib was modeled into the active site of ROS1 ( Figure 3E ). In this structure, the quinoline nitrogen of cabozantinib makes a hinge contact with Met2029, an amide group attached to the bridge phenyl ring forms a pair of hydrogen bonds with the backbone carbonyl group of Gly2101 and the ε-amino group of Lys1980. Further contacts are made with a hydrogen bond between the amide group attached to the tail phenyl ring and the carboxyl group of Asp2102, and a π-π stacking interaction between the phenyl ring and Phe2103. In G2032R and L2026M mutant ROS1, while there is no hydrogen bond between the amide group attached to the tail phenyl ring and the carboxyl group of Asp2102, the other interactions are preserved. By preserving most of the interactions seen in the wild-type kinase, cabozantinib is able to achieve potent inhibition of both the G2032R and L2026M mutants.
Cabozantinib demonstrates antitumor activity in a patient with ROS1-rearranged NSCLC who progressed on crizotinib and multiple lines of cytotoxic chemotherapy
Given the efficacy of cabozantinib in preclinical models of ROS1-rearranged NSCLC, a 
To accelerate discovery of new therapeutics for ROS1-and NTRK1-rearranged lung cancer, a library of existing targeted agents was screened. Compounds were selected for further study based on potency, selectivity, and clinical availability.
Cabozantinib was the most promising ROS1 inhibitor identified because it inhibits both the wild-type ROS1 and the G2032R and L2026M mutants that confer resistance to crizotinib.
Unlike brigatinib, entrectinib, and PF-06463922, three drugs in clinical development as ROS1 inhibitors, cabozantinib is equally potent against wild-type and crizotinib-resistant (G2032R and L2026M) ROS1. Brigatinib and PF-06463922 were not present in our initial library, and were used to compare the efficacy of inhibition of wild-type ROS1 and the G2032R and L2026M mutations with cabozantinib. Cabozantinib is able to achieve potent inhibition of wild-type and crizotinib-resistant ROS1 by maintaining most of the interactions in the enzyme active site.
Cabozantinib is currently FDA-approved for the treatment of medullary thyroid carcinoma. Kinase inhibition occurs at concentrations ~50-fold less than the peak plasma level obtained through FDA-approved oral dosing ( Table 1) . As an FDA-approved drug, cabozantinib has been extensively studied in the clinic. In medullary thyroid cancer, cabozantinib increases the progression-free survival (11.2 months vs. 4 months) compared to placebo (24) .
Cabozantinib has also been studied in prostate cancer (25), RET-rearranged NSCLC, and renal cell carcinoma (26) . Of 3 patients with RET-rearranged NSCLC treated with cabozantinib, 2 experienced a partial response and 1 patient had stable disease (27) . In the phase III thyroid cancer study, adverse events including diarrhea, palmar-plantar erythrodysesthesia, weight loss, anorexia, and fatigue led to dose-reductions or discontinuation in 79% and 16% of patients, respectively (24).
Research. 
Based on the preclinical work presented here and in the available literature (20) , off-label cabozantinib treatment was used in a ROS1-rearranged NSCLC patient who had progressed after 13 months of crizotinib treatment and 3 other forms of systemic therapy. Cabozantinib was chosen over cytotoxic chemotherapy because the patient's lung cancer had previously progressed on cisplatin + pemetrexed, carboplatin + gemcitabine, erlotinib, and crizotinib. The FDAapproved dose of 140 mg daily was chosen given the patient's symptomatic progression on crizotinib. Her symptoms of cough and dyspnea rapidly improved on the 140 mg cabozantinib dose, and radiographic improvement was apparent 4 weeks later. This is consistent with the prompt responses seen to erlotinib/gefitinib and crizotinib in EGFR mutant and ALK-rearranged NSCLC.
Unfortunately, it appeared that the therapeutic window of cabozantinib overlapped with toxic levels in our patient. In the clinical trial of cabozantinib in medullary thyroid cancer, 79% of patients had dose reductions, and 65% of patients had doses held (24) . The clinical trial of cabozantinib in prostate cancer attempted to address this issue by using either 40 mg or 100 mg doses (25). The rate of dose reduction was 84% in the 100 mg group and 31% in the 40 mg group, with discontinuation rates of 25% and 18%, respectively.
Ceritinib, an ALK inhibitor, is effective in crizotinib resistant cancers that do or do not contain an ALK secondary mutation (17) . The activity in the latter subgroup may be due to either the increased potency of ceritinib on ALK and/or the inhibition of other kinases such as IGFR1 inhibited by ceritinib but not crizotinib (28) . Analogously, the increased potency of cabozantinib on ROS1 may be the reason for the clinical benefit in our patient.
Analysis of the patient's tumor DNA using targeted next generation sequencing did not reveal any variants that could explain resistance to crizotinib. Specifically, we did not identify in our patient the G2032R or L2026M mutations that confer resistance to crizotinib, while maintaining sensitivity to cabozantinib. In patients with EGFR-mutant NSCLC and progression on an EGFR TKI, cabozantinib 40 mg daily with erlotinib resulted in an 11% response rate (29) , and this was attributed to targeting of resistance pathways including MET. It is possible that cabozantinib was active against a secondary pathway that caused resistance, in addition to more potently inhibiting wild-type ROS1 kinase.
Our patient had two ROS1-rearrangements involving intron 33 with EZR, which has previously been reported (9) , and with RNPC3 (RNA-binding region containing 3) on chromosome 1p21, which, to our knowledge, has not been previously reported. CD74 is the most common ROS1 fusion partner among the 11 different partners that have been reported (7, 9) . The RNPC3 gene encodes a 517 amino acid protein, RNA binding protein 40 (also known as U11/U12 snRNP 65k), that is a component of the U12-dependent (minor) spliceosome (30) . CD74-NTRK1, suggesting that both agents may still retain the ability to inhibit NTRK1 and downstream signaling including ERK even in the presence of the gatekeeper mutation.
A second potential explanation for these observations is that inhibition of CD74-NTRK1 F589V Ba/F3 cells by BMS-536924 and lestaurtinib is due to an off-target effect of these inhibitors. In order to differentiate between these two possibilities additional biochemical studies, to determine binding of BMS-536924 and lestaurtinib to NTRK1 and NTRK1 F589V, and mutagenesis studies, to introduce additional gatekeeper residues and solvent front mutations, will need to be performed. Given the ATP binding site homology observed amongst NTRK family members (31), the inhibitors reported here could be tested for inhibition of NTRK2 and NTRK3 in future studies.
Genetic sequencing efforts are identifying ever more rare subsets of patients with actionable driver oncogenes. The identification of new uses for existing targeted therapies in such patients is a way to rapidly deliver new treatments to the clinic, while avoiding the high cost of de novo drug development. This strategy may also be deployed to overcome resistance to targeted therapies across a variety of oncogene-addicted cancers. As new uses are discovered for existing targeted therapies, patients should be encouraged to participate in clinical trials of these agents, rather than be used as a rationale for off-protocol, non-trial use of such drugs.
